Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy Article Swipe
Akinori Minato
,
Nobuki Furubayashi
,
Toshihisa Tomoda
,
Hiroyuki Masaoka
,
YOOHYUN SONG
,
Yoshifumi Hori
,
KEIJIRO KIYOSHIMA
,
Takahito Negishi
,
Kentaro Kuroiwa
,
Narihito Seki
,
Ikko Tomisaki
,
Motonobu Nakamura
,
Kenichi Harada
,
Naohiro Fujimoto
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.21873/anticanres.17162
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.21873/anticanres.17162
EV monotherapy after avelumab maintenance therapy provides favorable survival outcomes in patients with advanced UC.
Related Topics
Concepts
Pembrolizumab
Avelumab
Urothelial carcinoma
Medicine
Oncology
Internal medicine
Carcinoma
Immunotherapy
Cancer
Bladder cancer
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.21873/anticanres.17162
- https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdf
- OA Status
- hybrid
- Cited By
- 10
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401022597
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401022597Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21873/anticanres.17162Digital Object Identifier
- Title
-
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab TherapyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-07-26Full publication date if available
- Authors
-
Akinori Minato, Nobuki Furubayashi, Toshihisa Tomoda, Hiroyuki Masaoka, YOOHYUN SONG, Yoshifumi Hori, KEIJIRO KIYOSHIMA, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Motonobu Nakamura, Kenichi Harada, Naohiro FujimotoList of authors in order
- Landing page
-
https://doi.org/10.21873/anticanres.17162Publisher landing page
- PDF URL
-
https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdfDirect OA link when available
- Concepts
-
Pembrolizumab, Avelumab, Urothelial carcinoma, Medicine, Oncology, Internal medicine, Carcinoma, Immunotherapy, Cancer, Bladder cancerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 10Per-year citation counts (last 5 years)
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401022597 |
|---|---|
| doi | https://doi.org/10.21873/anticanres.17162 |
| ids.doi | https://doi.org/10.21873/anticanres.17162 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39060065 |
| ids.openalex | https://openalex.org/W4401022597 |
| fwci | 12.48635117 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D061067 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D061067 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008297 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Male |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005260 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Female |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D000368 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Aged |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D008875 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Middle Aged |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D000369 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Aged, 80 and over |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D012189 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Retrospective Studies |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D014571 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Urologic Neoplasms |
| mesh[10].qualifier_ui | Q000473 |
| mesh[10].descriptor_ui | D014571 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pathology |
| mesh[10].descriptor_name | Urologic Neoplasms |
| mesh[11].qualifier_ui | Q000401 |
| mesh[11].descriptor_ui | D014571 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | mortality |
| mesh[11].descriptor_name | Urologic Neoplasms |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D016896 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Treatment Outcome |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D002295 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Carcinoma, Transitional Cell |
| mesh[14].qualifier_ui | Q000401 |
| mesh[14].descriptor_ui | D002295 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | mortality |
| mesh[14].descriptor_name | Carcinoma, Transitional Cell |
| mesh[15].qualifier_ui | Q000473 |
| mesh[15].descriptor_ui | D002295 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | pathology |
| mesh[15].descriptor_name | Carcinoma, Transitional Cell |
| mesh[16].qualifier_ui | Q000627 |
| mesh[16].descriptor_ui | D000911 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | therapeutic use |
| mesh[16].descriptor_name | Antibodies, Monoclonal |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D000074322 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D000328 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Adult |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D000971 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D000077982 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Progression-Free Survival |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D000082082 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D006801 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Humans |
| mesh[23].qualifier_ui | Q000627 |
| mesh[23].descriptor_ui | D061067 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | therapeutic use |
| mesh[23].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[24].qualifier_ui | Q000008 |
| mesh[24].descriptor_ui | D061067 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | administration & dosage |
| mesh[24].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D008297 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Male |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D005260 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Female |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D000368 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Aged |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D008875 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Middle Aged |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D000369 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Aged, 80 and over |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D012189 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Retrospective Studies |
| mesh[31].qualifier_ui | Q000188 |
| mesh[31].descriptor_ui | D014571 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | drug therapy |
| mesh[31].descriptor_name | Urologic Neoplasms |
| mesh[32].qualifier_ui | Q000473 |
| mesh[32].descriptor_ui | D014571 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | pathology |
| mesh[32].descriptor_name | Urologic Neoplasms |
| mesh[33].qualifier_ui | Q000401 |
| mesh[33].descriptor_ui | D014571 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | mortality |
| mesh[33].descriptor_name | Urologic Neoplasms |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D016896 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Treatment Outcome |
| mesh[35].qualifier_ui | Q000188 |
| mesh[35].descriptor_ui | D002295 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | drug therapy |
| mesh[35].descriptor_name | Carcinoma, Transitional Cell |
| mesh[36].qualifier_ui | Q000401 |
| mesh[36].descriptor_ui | D002295 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | mortality |
| mesh[36].descriptor_name | Carcinoma, Transitional Cell |
| mesh[37].qualifier_ui | Q000473 |
| mesh[37].descriptor_ui | D002295 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | pathology |
| mesh[37].descriptor_name | Carcinoma, Transitional Cell |
| mesh[38].qualifier_ui | Q000627 |
| mesh[38].descriptor_ui | D000911 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | therapeutic use |
| mesh[38].descriptor_name | Antibodies, Monoclonal |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D000074322 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Antineoplastic Agents, Immunological |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D000328 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Adult |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D000971 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D000077982 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Progression-Free Survival |
| mesh[43].qualifier_ui | Q000627 |
| mesh[43].descriptor_ui | D000082082 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | therapeutic use |
| mesh[43].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D006801 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Humans |
| mesh[45].qualifier_ui | Q000627 |
| mesh[45].descriptor_ui | D061067 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | therapeutic use |
| mesh[45].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[46].qualifier_ui | Q000008 |
| mesh[46].descriptor_ui | D061067 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | administration & dosage |
| mesh[46].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D008297 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Male |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D005260 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Female |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D000368 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Aged |
| type | article |
| title | Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy |
| biblio.issue | 8 |
| biblio.volume | 44 |
| biblio.last_page | 3426 |
| biblio.first_page | 3419 |
| topics[0].id | https://openalex.org/T10458 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Bladder and Urothelial Cancer Treatments |
| topics[1].id | https://openalex.org/T12695 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9966999888420105 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Urinary and Genital Oncology Studies |
| topics[2].id | https://openalex.org/T10619 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9843000173568726 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Esophageal Cancer Research and Treatment |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780057760 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9113947153091431 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[0].display_name | Pembrolizumab |
| concepts[1].id | https://openalex.org/C2777381376 |
| concepts[1].level | 5 |
| concepts[1].score | 0.8915489912033081 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q21083261 |
| concepts[1].display_name | Avelumab |
| concepts[2].id | https://openalex.org/C3019882237 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6817820072174072 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[2].display_name | Urothelial carcinoma |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.6115439534187317 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.600324273109436 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5507314801216125 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2777546739 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4749298691749573 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q33525 |
| concepts[6].display_name | Carcinoma |
| concepts[7].id | https://openalex.org/C2777701055 |
| concepts[7].level | 3 |
| concepts[7].score | 0.3821450471878052 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[7].display_name | Immunotherapy |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.22439107298851013 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C2780352672 |
| concepts[9].level | 3 |
| concepts[9].score | 0.19674572348594666 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q504775 |
| concepts[9].display_name | Bladder cancer |
| keywords[0].id | https://openalex.org/keywords/pembrolizumab |
| keywords[0].score | 0.9113947153091431 |
| keywords[0].display_name | Pembrolizumab |
| keywords[1].id | https://openalex.org/keywords/avelumab |
| keywords[1].score | 0.8915489912033081 |
| keywords[1].display_name | Avelumab |
| keywords[2].id | https://openalex.org/keywords/urothelial-carcinoma |
| keywords[2].score | 0.6817820072174072 |
| keywords[2].display_name | Urothelial carcinoma |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.6115439534187317 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.600324273109436 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.5507314801216125 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/carcinoma |
| keywords[6].score | 0.4749298691749573 |
| keywords[6].display_name | Carcinoma |
| keywords[7].id | https://openalex.org/keywords/immunotherapy |
| keywords[7].score | 0.3821450471878052 |
| keywords[7].display_name | Immunotherapy |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.22439107298851013 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/bladder-cancer |
| keywords[9].score | 0.19674572348594666 |
| keywords[9].display_name | Bladder cancer |
| language | en |
| locations[0].id | doi:10.21873/anticanres.17162 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S157347057 |
| locations[0].source.issn | 0250-7005, 1791-7530 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0250-7005 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Anticancer Research |
| locations[0].source.host_organization | https://openalex.org/P4320800545 |
| locations[0].source.host_organization_name | International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts |
| locations[0].source.host_organization_lineage | https://openalex.org/P4320800545 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Anticancer Research |
| locations[0].landing_page_url | https://doi.org/10.21873/anticanres.17162 |
| locations[1].id | pmid:39060065 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Anticancer research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39060065 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5082566636 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6303-1128 |
| authorships[0].author.display_name | Akinori Minato |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I188700360 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I188700360 |
| authorships[0].institutions[0].ror | https://ror.org/020p3h829 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I188700360 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | University of Occupational and Environmental Health Japan |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | AKINORI MINATO |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan |
| authorships[1].author.id | https://openalex.org/A5071222216 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-9159-493X |
| authorships[1].author.display_name | Nobuki Furubayashi |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[1].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | NOBUKI FURUBAYASHI |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan |
| authorships[2].author.id | https://openalex.org/A5073793517 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Toshihisa Tomoda |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210118246 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Urology, Oita Prefectural Hospital, Oita, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I4210118246 |
| authorships[2].institutions[0].ror | https://ror.org/029fzbq43 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210118246 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Oita Prefectural Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | TOSHIHISA TOMODA |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Urology, Oita Prefectural Hospital, Oita, Japan |
| authorships[3].author.id | https://openalex.org/A5039908829 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-1990-5937 |
| authorships[3].author.display_name | Hiroyuki Masaoka |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210134884 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I4210134884 |
| authorships[3].institutions[0].ror | https://ror.org/02sttfr93 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210134884 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | HIROYUKI MASAOKA |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan |
| authorships[4].author.id | https://openalex.org/A5101386722 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | YOOHYUN SONG |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210134884 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I4210134884 |
| authorships[4].institutions[0].ror | https://ror.org/02sttfr93 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210134884 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | YOOHYUN SONG |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan |
| authorships[5].author.id | https://openalex.org/A5111082789 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Yoshifumi Hori |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210108863 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I4210108863 |
| authorships[5].institutions[0].ror | https://ror.org/01pxhdc49 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210108863 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Miyazaki Prefectural Hospital |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | YOSHIFUMI HORI |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan |
| authorships[6].author.id | https://openalex.org/A5089070060 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | KEIJIRO KIYOSHIMA |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210115119 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I4210115119 |
| authorships[6].institutions[0].ror | https://ror.org/022mjvt30 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I2799517759, https://openalex.org/I4210115119 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Japanese Red Cross Fukuoka Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | KEIJIRO KIYOSHIMA |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan |
| authorships[7].author.id | https://openalex.org/A5012284662 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-6645-8829 |
| authorships[7].author.display_name | Takahito Negishi |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[7].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | TAKAHITO NEGISHI |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan |
| authorships[8].author.id | https://openalex.org/A5017068775 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Kentaro Kuroiwa |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210108863 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210108863 |
| authorships[8].institutions[0].ror | https://ror.org/01pxhdc49 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210108863 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Miyazaki Prefectural Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | KENTARO KUROIWA |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan |
| authorships[9].author.id | https://openalex.org/A5109753471 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Narihito Seki |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210134884 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan |
| authorships[9].institutions[0].id | https://openalex.org/I4210134884 |
| authorships[9].institutions[0].ror | https://ror.org/02sttfr93 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210134884 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | NARIHITO SEKI |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan |
| authorships[10].author.id | https://openalex.org/A5081326354 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-7818-0780 |
| authorships[10].author.display_name | Ikko Tomisaki |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I188700360 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan |
| authorships[10].institutions[0].id | https://openalex.org/I188700360 |
| authorships[10].institutions[0].ror | https://ror.org/020p3h829 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I188700360 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | University of Occupational and Environmental Health Japan |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | IKKO TOMISAKI |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan |
| authorships[11].author.id | https://openalex.org/A5102955473 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-3038-1361 |
| authorships[11].author.display_name | Motonobu Nakamura |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210093709 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan |
| authorships[11].institutions[0].id | https://openalex.org/I4210093709 |
| authorships[11].institutions[0].ror | https://ror.org/00mce9b34 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210093709, https://openalex.org/I4210137409 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | National Hospital Organization Kyushu Cancer Center |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | MOTONOBU NAKAMURA |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan |
| authorships[12].author.id | https://openalex.org/A5103635551 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Kenichi Harada |
| authorships[12].countries | JP |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I188700360 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan |
| authorships[12].institutions[0].id | https://openalex.org/I188700360 |
| authorships[12].institutions[0].ror | https://ror.org/020p3h829 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I188700360 |
| authorships[12].institutions[0].country_code | JP |
| authorships[12].institutions[0].display_name | University of Occupational and Environmental Health Japan |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | KENICHI HARADA |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan |
| authorships[13].author.id | https://openalex.org/A5020076297 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-5256-6415 |
| authorships[13].author.display_name | Naohiro Fujimoto |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Urology, Kurate Hospital, Kurate, Japan |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | NAOHIRO FUJIMOTO |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Urology, Kurate Hospital, Kurate, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10458 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Bladder and Urothelial Cancer Treatments |
| related_works | https://openalex.org/W4238705971, https://openalex.org/W3031689938, https://openalex.org/W2886372711, https://openalex.org/W4353088123, https://openalex.org/W2945129799, https://openalex.org/W4245854978, https://openalex.org/W2768197926, https://openalex.org/W4254491264, https://openalex.org/W4250290904, https://openalex.org/W3113058462 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 10 |
| locations_count | 2 |
| best_oa_location.id | doi:10.21873/anticanres.17162 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S157347057 |
| best_oa_location.source.issn | 0250-7005, 1791-7530 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0250-7005 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Anticancer Research |
| best_oa_location.source.host_organization | https://openalex.org/P4320800545 |
| best_oa_location.source.host_organization_name | International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4320800545 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Anticancer Research |
| best_oa_location.landing_page_url | https://doi.org/10.21873/anticanres.17162 |
| primary_location.id | doi:10.21873/anticanres.17162 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S157347057 |
| primary_location.source.issn | 0250-7005, 1791-7530 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0250-7005 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Anticancer Research |
| primary_location.source.host_organization | https://openalex.org/P4320800545 |
| primary_location.source.host_organization_name | International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts |
| primary_location.source.host_organization_lineage | https://openalex.org/P4320800545 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://ar.iiarjournals.org/content/anticanres/44/8/3419.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Anticancer Research |
| primary_location.landing_page_url | https://doi.org/10.21873/anticanres.17162 |
| publication_date | 2024-07-26 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4391600406, https://openalex.org/W2121960517, https://openalex.org/W4386283669, https://openalex.org/W2943108118, https://openalex.org/W4391302611, https://openalex.org/W3087464965, https://openalex.org/W2132379894, https://openalex.org/W4391303599, https://openalex.org/W4392718644, https://openalex.org/W4392498919, https://openalex.org/W4400084176, https://openalex.org/W4386530351, https://openalex.org/W2019607817, https://openalex.org/W4366339435, https://openalex.org/W4392771714, https://openalex.org/W2588916311, https://openalex.org/W4387859553, https://openalex.org/W3127912627, https://openalex.org/W4394615721, https://openalex.org/W4388419355, https://openalex.org/W4392296099, https://openalex.org/W4319302734 |
| referenced_works_count | 22 |
| abstract_inverted_index.EV | 0 |
| abstract_inverted_index.in | 10 |
| abstract_inverted_index.UC. | 14 |
| abstract_inverted_index.with | 12 |
| abstract_inverted_index.after | 2 |
| abstract_inverted_index.therapy | 5 |
| abstract_inverted_index.advanced | 13 |
| abstract_inverted_index.avelumab | 3 |
| abstract_inverted_index.outcomes | 9 |
| abstract_inverted_index.patients | 11 |
| abstract_inverted_index.provides | 6 |
| abstract_inverted_index.survival | 8 |
| abstract_inverted_index.favorable | 7 |
| abstract_inverted_index.maintenance | 4 |
| abstract_inverted_index.monotherapy | 1 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 98 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 14 |
| citation_normalized_percentile.value | 0.97890366 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |